Liver cancer patients see longer survival with dual immunotherapy approach
Medical Xpress
JUNE 16, 2025
A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) has pioneered the use of a 'dual immunotherapy' combination—nivolumab and ipilimumab (NIVO+IPI)—in the treatment of liver cancer patients since 2016.
Let's personalize your content